Sg3 Management, LLC Avadel Pharmaceuticals PLC Call Options Transaction History

Sg3 Management, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $72,072 - $109,427	-13,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $85,668 - $130,812	13,200 New	13,200 $129,000
Q2 2020 Aug 14, 2020	SELL	$7.25 - $11.75 $108,750 - $176,250	-15,000 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$4.06 - $10.64 $60,899 - $159,600	15,000 New	15,000 $119,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.